
Jesus Anampa Mesias
Advertisement
Articles by Jesus Anampa Mesias


24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study
BySara A. Hurvitz, MD,Anne F. Schott, MD,Cynthia X. Ma, MD, PhD,Erika P. Hamilton, MD,Rita Nanda, MD,George Zahrah,Natasha Hunter, MD,Antoinette R. Tan,Melinda L. Telli, MD,Jesus Anampa Mesias,Rinath Jeselsohn,Pamela N. Munster, MD,Haolan Lu,Richard Gedrich,Cecile Mather,Janaki Parameswaran,Hyo S Han
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Metformin Yields No Benefit in Low-Risk Prostate Cancer on Active Surveillance
2
Chemoradiotherapy Regimen May Show Viability in Recurrent HNSCC
3
SBRT Alone Yields Significant STFS, Manageable Toxicity in Oligometastatic Cancer
4
Investigational NDA Submitted to FDA for CD-19+ Lymphoma/Leukemia
5

